

Supplementary Table S1. Fraction of CC patients with lymph nodes belonging to any of the three categories CXCL17(-)CEA(+), CXCL17(-)CEA(int) and CXCL17(-)CEA(-) that have died in cancer during the 12 years observation period

All CC patients		CXCL17(-)CEA(+)			CXCL17(-)CEA(int)			CXCL17(-)CEA(-)		
Stage	n	n	H&E(+)	Dead in CC	n	H&E(+)	Dead in CC	n	H&E(+)	Dead in CC
I	23	1	1	0/1	6	0/6	0/6	7	0/7	0/7
II	52	0	-	-	12	0/12	0/12	17	0/17	2/17
III	36	1	0/1	1/1	2	0/2	0/0	12	0/12	3/12
IV	9	0	-	-	1	0/1	0/1	0	-	-

° H&E status of the lymph node referring the patient to the indicated CXCL17/CEA mRNA category. Data are expressed as H&E(+) lymph nodes/total number of lymph nodes in the respective category.

Note that in several cases the investigators did not have access to the lymph node(s) that referred patients to stage III by H&E examination.